Literature DB >> 109535

Gene dose effects in Ir gene-controlled systems.

M E Dorf, J H Stimpfling, B Benacerraf.   

Abstract

(B10.A x B10.S)F1 hybrid mice produce lower levels of anti-GL phi antibody than B10.S(9R) and B10.HTT mice. To determine whether this difference is due to a gene dose or a cis-trans effect, [B10.S(9R) x B10.S(8R)]F1 mice were immunized with GL phi. These mice carry one dose of the responder Ir gene alleles in the cis position whereas the recombinant B10.S(9R) and B10.HTT mice carry two doses of the relevant genes. Both (B10.A x B10.S) and [B10.S(9R) x B10.S(8R)] F1 mice produced comparably lower amounts of antibodies as compared to the recombinant strains. The data therefore demonstrate that gene dose and not cis-trans effect accounts for the differences between F1 and recombinant strains in their antibody response to GL phi controlled by complementary Ir genes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109535

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  The course of malaria in mice: major histocompatibility complex (MHC) effects, but no general MHC heterozygote advantage in single-strain infections.

Authors:  Claus Wedekind; Mirjam Walker; Tom J Little
Journal:  Genetics       Date:  2005-05-23       Impact factor: 4.562

2.  Major histocompatibility complex heterozygosity reduces fitness in experimentally infected mice.

Authors:  Petteri Ilmonen; Dustin J Penn; Kristy Damjanovich; Linda Morrison; Laleh Ghotbi; Wayne K Potts
Journal:  Genetics       Date:  2007-07-01       Impact factor: 4.562

3.  Immune response gene function correlates with the expression of an Ia antigen. I. Preferential association of certain Ae and E alpha chains results in a quantitative deficiency in expression of an Ae:E alpha complex.

Authors:  J M McNicholas; D B Murphy; L A Matis; R H Schwartz; E A Lerner; C A Janeway; P P Jones
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.